Grail Inc Stock Price, News & Analysis

GRAIL (Nasdaq: GRAL), a healthcare company focused on early cancer detection, has announced its participation in the Canaccord Genuity 45th Annual Growth Conference. The presentation is scheduled for Wednesday, August 13 at 8:30 a.m. ET in Boston.

Investors can access both live and replay webcasts through GRAIL's investor relations website at investors.grail.com. The webcast recording will remain available for a minimum of 30 days following the event.

GRAIL (Nasdaq: GRAL), a healthcare company focused on early cancer detection, will release its Q2 2025 financial results on Tuesday, August 12, 2025 after market close. Management will host a conference call and webcast at 1:30 PM PT / 4:30 PM ET to discuss the results and business progress.

Interested parties can access the live webcast through GRAIL's investor relations website at investors.grail.com. Participants are advised to register at least ten minutes before the call's scheduled start time through the provided registration link.

GRAIL (GRAL) announced positive top-line results from its PATHFINDER 2 registrational study evaluating the Galleri multi-cancer early detection test. The study, involving 25,578 participants aged 50+ with no cancer suspicion, showed substantially higher cancer detection rates and positive predictive value compared to the previous PATHFINDER study. The Galleri test, when added to standard cancer screening, maintained high specificity (99.5%) and cancer signal origin accuracy (88%) while demonstrating improved positive predictive value from the previous 43%. No serious safety concerns were reported. GRAIL plans to submit these results, along with NHS-Galleri trial data, to the FDA as part of Galleri's premarket approval application under Breakthrough Device Designation, with complete submission expected in H1 2026.

GRAIL (NASDAQ: GRAL), a healthcare company focused on early cancer detection, has awarded restricted stock units (RSUs) to 38 new non-executive employees as employment inducement grants. The RSUs cover 77,350 shares of GRAIL common stock and were granted under the company's Inducement Equity Incentive Plan in compliance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over approximately four years, with 25% vesting on May 31, 2026, and the remaining portions vesting annually thereafter, contingent on continued employment with GRAIL or its subsidiaries.

GRAIL (NASDAQ: GRAL), a healthcare company focused on early cancer detection, has announced its participation in the upcoming Jefferies Global Healthcare Conference 2025. The company's management will deliver a presentation on Tuesday, June 4 at 11:40 a.m. ET in New York. Investors and interested parties can access both live and replay webcasts of the presentation through GRAIL's investor relations website at investors.grail.com. The webcast recording will remain available for a minimum of 30 days following the event.

GRAIL (NASDAQ: GRAL) reported its Q1 2025 financial results, showing significant growth in its cancer detection business. Total revenue reached $31.8M (19% YoY growth), with U.S. Galleri revenue at $28.7M (22% YoY growth). The company completed over 37,000 Galleri tests in Q1. Despite growth, GRAIL posted a net loss of $106.2M, though this represents a 51% improvement YoY. The company maintains a strong cash position of $677.9M, providing runway into 2028. Notably, GRAIL announced positive top-line results from the NHS-Galleri trial's prevalent screening round, showing higher positive predictive value than the PATHFINDER study, while maintaining consistent cancer signal origin accuracy and specificity. The company plans to submit data for premarket approval in H1 2026. Key partnerships include integration with athenahealth's EHR platform and a new educational initiative with actress Kate Walsh called Generation Possible.

GRAIL (NASDAQ: GRAL) has announced a strategic partnership with athenahealth to integrate its Galleri® multi-cancer early detection (MCED) test into athenaCoordinator Core. The integration will enable over 160,000 U.S. clinicians on athenahealth's network to seamlessly order the Galleri test through their electronic health record (EHR) system.

The Galleri test, which detects cancer through DNA fragments in blood samples, can screen for multiple deadly cancers before symptoms appear and identify the cancer's origin. The test is prescription-only and recommended for adults with elevated cancer risk, particularly those 50 or older, complementing existing cancer screening methods.

This partnership aims to streamline the ordering process, reduce administrative burden, and increase patient access to early cancer detection services.

GRAIL (Nasdaq: GRAL), a healthcare company focused on early cancer detection, has scheduled its first quarter 2025 financial results announcement for Tuesday, May 13, 2025, after market close.

The company will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss their financial performance and business progress. Interested parties can access the live webcast through GRAIL's investor relations website at investors.grail.com.

To participate, attendees should:

• Register via https://grail-q1-financial-results-2025.open-exchange.net/
• Connect at least ten minutes before the scheduled start
• Access the investor relations section for live and recorded webcasts

GRAIL (NASDAQ: GRAL) will present new data on its Galleri® multi-cancer early detection (MCED) test at the AACR Annual Meeting in Chicago, April 25-30, 2025. The presentations include real-world evidence from over 100,000 patients, validating the test's capability to detect multiple cancers and accurately predict cancer signal origin.

Key findings include:

• Confirmation of the test's ability to detect cancer signals across various cancer types, particularly those without recommended screening
• Evidence showing reduced cancer risk for one year post-blood draw in patients receiving negative results
• Data supporting annual screening recommendations
• New insights from GRAIL's ctDNA-based targeted methylation platform, demonstrating potential for cancer subtyping through blood samples